LifeCell Corp. announced that AlloDerm, its proprietary dermalskin replacement tissue, demonstrated 93 percent take in 18patients with deep third-degree burns enrolled in the secondphase of the companyUs clinical evaluation. LifeCell (NASDAQ:LIFC) presented the data at the annual meeting of theAmerican Association of Tissue Banks in Boston.
The rate was statistically equivalent to control sites graftedwith the patientUs own skin and indicates the absence of arejection response. The take rate of the patientUs epithelialgrafts applied simultaneously to the surface of the graftedAlloDerm was also high (88 percent).
Clinical studies for AlloDerm are currently under way at nineU.S. burn centers. LifeCell of The Woodlands, Texas, planscommercial introduction of the product late this year.
(c) 1997 American Health Consultants. All rights reserved.